New Product Newswire

Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.

Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.

GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.

The expanded indication now includes patients aged 5 through 11 years in addition to those aged 12 through 65 years.